Targeted Alteration of Antibody-Based Immunodominance Enhances the Heterosubtypic Immunity of an Experimental PCV2 Vaccine
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cells and Viruses
2.2. Cloning of the Vaccine Construct
2.3. Insertion of a Marker to Enable the Monitoring of Vaccine Compliance
2.4. Preparation of PCV2 Virus Cultures
2.5. Immunofluorescence Assay
2.6. In-Vitro Vaccine Stability
2.7. Vaccination and Challenge of Piglets
2.8. Anti-PCV2 IgG Responses
2.9. Virus Neutralizing Antibody Responses
2.10. Antibody Responses to the Mutated Epitopes
2.11. Antibody Responses to the Marker
2.12. Measurement of Vaccine Viral Replication by qPCR
2.13. Detection of Challenge Viral Replication
2.14. Assessment of Pathological Lesions
2.15. Statistical Analysis
3. Results
3.1. The rPCV2-Vac Was Successfully Rescued and Expressed the Marker Peptide
3.2. The rPCV2-Vac Induces Binding Antibody Responses in Vaccinated Pigs
3.3. The rPCV2-Vac Elicits Broad Virus Neutralization Responses
3.4. Surface Plamon Resonance (SPR) Analysis of Epitope Binding
3.5. Measurement of the Marker Specific ab Responses
3.6. Vaccination Protects Against Challenge Viral Replication
3.7. Protection against Gross and Histological Lesions
3.8. Vaccination Protects against Weight Loss Due to Challenge
4. Discussion
5. Conclusions
6. Patents
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Afghah, Z.; Webb, B.; Meng, X.J.; Ramamoorthy, S. Ten years of PCV2 vaccines and vaccination: Is eradication a possibility? Vet. Microbiol. 2017, 206, 21–28. [Google Scholar] [CrossRef] [PubMed]
- Karuppannan, A.K.; Opriessnig, T. Porcine Circovirus Type 2 (PCV2) Vaccines in the Context of Current Molecular Epidemiology. Viruses 2017, 9, 99. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ssemadaali, M.A.; Ilha, M.; Ramamoorthy, S. Genetic diversity of porcine circovirus type 2 and implications for detection and control. Res. Vet. Sci. 2015, 103, 179–186. [Google Scholar] [CrossRef] [PubMed]
- Pogranichnyy, R.M.; Yoon, K.J.; Harms, P.A.; Swenson, S.L.; Zimmerman, J.J.; Sorden, S.D. Characterization of immune response of young pigs to porcine circovirus type 2 infection. Viral Immunol. 2000, 13, 143–153. [Google Scholar] [CrossRef]
- Nara, P.L. Deceptive imprinting: Insights into mechanisms of immune evasion and vaccine development. Adv. Vet. Med. 1999, 41, 115–134. [Google Scholar]
- Dvorak, C.M.; Yang, Y.; Haley, C.; Sharma, N.; Murtaugh, M.P. National reduction in porcine circovirus type 2 prevalence following introduction of vaccination. Vet. Microbiol. 2016, 189, 86–90. [Google Scholar] [CrossRef] [Green Version]
- Ilha, M.; Nara, P.; Ramamoorthy, S. Early antibody responses map to non-protective, PCV2 capsid protein epitopes. Virology 2020, 540, 23–29. [Google Scholar] [CrossRef]
- Trible, B.R.; Kerrigan, M.; Crossland, N.; Potter, M.; Faaberg, K.; Hesse, R.; Rowland, R.R. Antibody recognition of porcine circovirus type 2 capsid protein epitopes after vaccination, infection, and disease. Clin. Vaccine Immunol. 2011, 18, 749–757. [Google Scholar] [CrossRef] [Green Version]
- Trible, B.R.; Suddith, A.W.; Kerrigan, M.A.; Cino-Ozuna, A.G.; Hesse, R.A.; Rowland, R.R. Recognition of the different structural forms of the capsid protein determines the outcome following infection with porcine circovirus type 2. J. Virol. 2012, 86, 13508–13514. [Google Scholar] [CrossRef] [Green Version]
- Kolyvushko, O.; Rakibuzzaman, A.; Pillatzki, A.; Webb, B.; Ramamoorthy, S. Efficacy of a Commercial PCV2a Vaccine with a Two-Dose Regimen Against PCV2d. Vet. Sci. 2019, 6, 61. [Google Scholar] [CrossRef] [Green Version]
- Schwartz, R.M.; Dayhoff, M.O. Protein and nucleic Acid sequence data and phylogeny. Science 1979, 205, 1038–1039. [Google Scholar] [CrossRef] [Green Version]
- Donahoe, S.L.; Lindsay, S.A.; Krockenberger, M.; Phalen, D.; Slapeta, J. A review of neosporosis and pathologic findings of Neospora caninum infection in wildlife. Int. J. Parasitol. Parasites Wildl. 2015, 4, 216–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fenaux, M.; Opriessnig, T.; Halbur, P.G.; Meng, X.J. Immunogenicity and pathogenicity of chimeric infectious DNA clones of pathogenic porcine circovirus type 2 (PCV2) and nonpathogenic PCV1 in weanling pigs. J. Virol. 2003, 77, 11232–11243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fenaux, M.; Halbur, P.G.; Haqshenas, G.; Royer, R.; Thomas, P.; Nawagitgul, P.; Gill, M.; Toth, T.E.; Meng, X.J. Cloned genomic DNA of type 2 porcine circovirus is infectious when injected directly into the liver and lymph nodes of pigs: Characterization of clinical disease, virus distribution, and pathologic lesions. J. Virol. 2002, 76, 541–551. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bonifaz, L.C.; Arzate, S.; Moreno, J. Endogenous and exogenous forms of the same antigen are processed from different pools to bind MHC class II molecules in endocytic compartments. Eur. J. Immunol. 1999, 29, 119–131. [Google Scholar] [CrossRef]
- Fenaux, M.; Opriessnig, T.; Halbur, P.G.; Elvinger, F.; Meng, X.J. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs. J. Virol. 2004, 78, 6297–6303. [Google Scholar] [CrossRef] [Green Version]
- Beach, N.M.; Ramamoorthy, S.; Opriessnig, T.; Wu, S.Q.; Meng, X.J. Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs. Vaccine 2010, 29, 221–232. [Google Scholar] [CrossRef]
- Barnett, S.W.; Lu, S.; Srivastava, I.; Cherpelis, S.; Gettie, A.; Blanchard, J.; Wang, S.; Mboudjeka, I.; Leung, L.; Lian, Y.; et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 2001, 75, 5526–5540. [Google Scholar] [CrossRef] [Green Version]
- Jeffs, S.A.; Shotton, C.; Balfe, P.; McKeating, J.A. Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J. Gen. Virol. 2002, 83, 2723–2732. [Google Scholar] [CrossRef]
- Nara, P.L.; Tobin, G.J.; Chaudhuri, A.R.; Trujillo, J.D.; Lin, G.; Cho, M.W.; Levin, S.A.; Ndifon, W.; Wingreen, N.S. How can vaccines against influenza and other viral diseases be made more effective? PLoS Biol. 2010, 8, e1000571. [Google Scholar] [CrossRef]
- Zost, S.J.; Wu, N.C.; Hensley, S.E.; Wilson, I.A. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. J. Infect. Dis. 2019, 219, S38–S45. [Google Scholar] [CrossRef] [PubMed]
- Frei, J.C.; Wirchnianski, A.S.; Govero, J.; Vergnolle, O.; Dowd, K.A.; Pierson, T.C.; Kielian, M.; Girvin, M.E.; Diamond, M.S.; Lai, J.R. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice. J. Virol. 2018, 92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mahe, D.; Blanchard, P.; Truong, C.; Arnauld, C.; Le Cann, P.; Cariolet, R.; Madec, F.; Albina, E.; Jestin, A. Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes. J. Gen. Virol. 2000, 81, 1815–1824. [Google Scholar] [CrossRef] [PubMed]
- Garrity, R.R.; Rimmelzwaan, G.; Minassian, A.; Tsai, W.P.; Lin, G.; de Jong, J.J.; Goudsmit, J.; Nara, P.L. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 1997, 159, 279–289. [Google Scholar]
- Barker, W.C.; Dayhoff, M.O. Evolution of homologous physiological mechanisms based on protein sequence data. Comp. Biochem. Physiol. B Comp. Biochem. 1979, 62, 1–5. [Google Scholar] [CrossRef]
- Nayak, B.P.; Agarwal, A.; Nakra, P.; Rao, K.V. B cell responses to a peptide epitope. VIII. Immune complex-mediated regulation of memory B cell generation within germinal centers. J. Immunol. 1999, 163, 1371–1381. [Google Scholar]
- Rajewsky, K. Clonal selection and learning in the antibody system. Nature 1996, 381, 751–758. [Google Scholar] [CrossRef]
- Kittlesen, D.J.; Brown, L.R.; Braciale, V.L.; Sambrook, J.P.; Gething, M.J.; Braciale, T.J. Presentation of newly synthesized glycoproteins to CD4+ T lymphocytes. An analysis using influenza hemagglutinin transport mutants. J. Exp. Med. 1993, 177, 1021–1030. [Google Scholar] [CrossRef] [Green Version]
- Trujillo, J.D.; Kumpula-McWhirter, N.M.; Hotzel, K.J.; Gonzalez, M.; Cheevers, W.P. Glycosylation of immunodominant linear epitopes in the carboxy-terminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses. J. Virol. 2004, 78, 9190–9202. [Google Scholar] [CrossRef] [Green Version]
- Agarwal, A.; Rao, K.V. B cell responses to a peptide epitope: III. Differential T helper cell thresholds in recruitment of B cell fine specificities. J. Immunol. 1997, 159, 1077–1085. [Google Scholar]
- Singh, H.; Raghava, G.P. ProPred: Prediction of HLA-DR binding sites. Bioinformatics 2001, 17, 1236–1237. [Google Scholar] [CrossRef] [Green Version]
- Constans, M.; Ssemadaali, M.; Kolyvushko, O.; Ramamoorthy, S. Antigenic Determinants of Possible Vaccine Escape by Porcine Circovirus Subtype 2b Viruses. Bioinform. Biol. Insights 2015, 9, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.; Shim, E.H.; You, S. Immunodominance hierarchy of influenza subtype-specific neutralizing antibody response as a hurdle to effectiveness of polyvalent vaccine. Hum. Vaccines Immunother. 2018, 14, 2537–2539. [Google Scholar] [CrossRef] [PubMed]
- Seo, H.W.; Park, C.; Han, K.; Chae, C. Effect of porcine circovirus type 2 (PCV2) vaccination on PCV2-viremic piglets after experimental PCV2 challenge. Vet. Res. 2014, 45, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhai, S.L.; Chen, S.N.; Wei, Z.Z.; Zhang, J.W.; Huang, L.; Lin, T.; Yue, C.; Ran, D.L.; Yuan, S.S.; Wei, W.K.; et al. Co-existence of multiple strains of porcine circovirus type 2 in the same pig from China. Virol. J. 2011, 8, 517. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lovgren, T.; Baumgaertner, P.; Wieckowski, S.; Devevre, E.; Guillaume, P.; Luescher, I.; Rufer, N.; Speiser, D.E. Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol. Immunother. 2012, 61, 817–826. [Google Scholar] [CrossRef] [Green Version]
- Fort, M.; Sibila, M.; Allepuz, A.; Mateu, E.; Roerink, F.; Segales, J. Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins. Vaccine 2008, 26, 1063–1071. [Google Scholar] [CrossRef]
- Francis, M.J. Recent Advances in Vaccine Technologies. Vet. Clin. N. Am. Small Animal Pract. 2018, 48, 231–241. [Google Scholar] [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rakibuzzaman, A.; Kolyvushko, O.; Singh, G.; Nara, P.; Piñeyro, P.; Leclerc, E.; Pillatzki, A.; Ramamoorthy, S. Targeted Alteration of Antibody-Based Immunodominance Enhances the Heterosubtypic Immunity of an Experimental PCV2 Vaccine. Vaccines 2020, 8, 506. https://doi.org/10.3390/vaccines8030506
Rakibuzzaman A, Kolyvushko O, Singh G, Nara P, Piñeyro P, Leclerc E, Pillatzki A, Ramamoorthy S. Targeted Alteration of Antibody-Based Immunodominance Enhances the Heterosubtypic Immunity of an Experimental PCV2 Vaccine. Vaccines. 2020; 8(3):506. https://doi.org/10.3390/vaccines8030506
Chicago/Turabian StyleRakibuzzaman, AGM, Oleksandr Kolyvushko, Gagandeep Singh, Peter Nara, Pablo Piñeyro, Estelle Leclerc, Angela Pillatzki, and Sheela Ramamoorthy. 2020. "Targeted Alteration of Antibody-Based Immunodominance Enhances the Heterosubtypic Immunity of an Experimental PCV2 Vaccine" Vaccines 8, no. 3: 506. https://doi.org/10.3390/vaccines8030506